Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis

Immunity

Volumn 50, Issue 4, 2019, Pages 1099-1114.e10

  Castro Dopico, Tomas ^a   Dennison, Thomas W ^a   Ferdinand, John R ^a   Mathews, Rebeccah J ^a   Fleming, Aaron ^a   Clift, Dean ^b   Stewart, Benjamin J ^a   Jing, Chenzhi ^a   Strongili, Konstantina ^c   Labzin, Larisa I ^b   Monk, Edward J M ^a   Saeb Parsy, Kourosh ^d   Bryant, Clare E ^e   Clare, Simon ^f   Parkes, Miles ^c   Clatworthy, Menna R ^a,f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Fc receptors; IgG; IL 1 ; inflammatory bowel disease; type 17 immunity

Indexed keywords

CRYOPYRIN; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 8; REACTIVE OXYGEN METABOLITE; BACTERIUM ANTIBODY; DEXTRAN SULFATE; FC RECEPTOR IIA; MESSENGER RNA;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; COLON MUCOSA; COLONIC LAMINA PROPRIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; ENTERITIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MACROPHAGE; MOLECULAR MECHANICS; MOUSE MODEL; MURINE MODEL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANIMAL; BIOSYNTHESIS; COLITIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA; MICROBIOLOGY; MOUSE; PATHOLOGY; PHAGOCYTE; TH17 CELL;

ANIMALS; ANTIBODIES, BACTERIAL; COLITIS; COLITIS, ULCERATIVE; DEXTRAN SULFATE; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-8; INTESTINAL MUCOSA; MACROPHAGES; MICE; PHAGOCYTES; REACTIVE OXYGEN SPECIES; RECEPTORS, IGG; RNA, MESSENGER; TH17 CELLS;

EID: 85064143585     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2019.02.006     Document Type: Article

References (58)

1. Abraham, C., Cho, J.H., Functional consequences of NOD2 (CARD15) mutations. Inflamm. Bowel Dis. 12 (2006), 641–650.
2. Aibar, S., González-Blas, C.B., Moerman, T., Huynh-Thu, V.A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.C., Geurts, P., Aerts, J., et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14 (2017), 1083–1086.
3. Arijs, I., De Hertogh, G., Lemaire, K., Quintens, R., Van Lommel, L., Van Steen, K., Leemans, P., Cleynen, I., Van Assche, G., Vermeire, S., et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS ONE, 4, 2009, e7984.
4. Arijs, I., Li, K., Toedter, G., Quintens, R., Van Lommel, L., Van Steen, K., Leemans, P., De Hertogh, G., Lemaire, K., Ferrante, M., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58 (2009), 1612–1619.
5. Asano, K., Matsushita, T., Umeno, J., Hosono, N., Takahashi, A., Kawaguchi, T., Matsumoto, T., Matsui, T., Kakuta, Y., Kinouchi, Y., et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat. Genet. 41 (2009), 1325–1329.
6. Bain, C.C., Bravo-Blas, A., Scott, C.L., Perdiguero, E.G., Geissmann, F., Henri, S., Malissen, B., Osborne, L.C., Artis, D., Mowat, A.M., Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 15 (2014), 929–937.
7. Baklien, K., Brandtzaeg, P., Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin. Exp. Immunol. 22 (1975), 197–209.
8. Bersudsky, M., Luski, L., Fishman, D., White, R.M., Ziv-Sokolovskaya, N., Dotan, S., Rider, P., Kaplanov, I., Aychek, T., Dinarello, C.A., et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut 63 (2014), 598–609.
9. Bolland, S., Ravetch, J.V., Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13 (2000), 277–285.
10. Bosques, C.J., Manning, A.M., Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs. Autoimmun. Rev. 15 (2016), 1081–1088.
11. Breynaert, C., Dresselaers, T., Perrier, C., Arijs, I., Cremer, J., Van Lommel, L., Van Steen, K., Ferrante, M., Schuit, F., Vermeire, S., et al. Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease. PLoS ONE, 8, 2013, e68876.
12. Brownlie, R.J., Lawlor, K.E., Niederer, H.A., Cutler, A.J., Xiang, Z., Clatworthy, M.R., Floto, R.A., Greaves, D.R., Lyons, P.A., Smith, K.G., Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J. Exp. Med. 205 (2008), 883–895.
13. Cătană, C.S., Berindan Neagoe, I., Cozma, V., Magdaş, C., Tăbăran, F., Dumitraşcu, D.L., Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 21 (2015), 5823–5830.
14. Chung, Y., Chang, S.H., Martinez, G.J., Yang, X.O., Nurieva, R., Kang, H.S., Ma, L., Watowich, S.S., Jetten, A.M., Tian, Q., Dong, C., Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30 (2009), 576–587.
15. Clatworthy, M.R., Fcy Receptor polymorphisms and susceptibility to infection. Ackerman, M., Nimmerjahn, F., (eds.) Antibody Fc: Linking Adaptive and Innate Immunity, 2014, Academic Press, 217–238.
16. Clatworthy, M.R., Smith, K.G., FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J. Exp. Med. 199 (2004), 717–723.
17. Clift, D., McEwan, W.A., Labzin, L.I., Konieczny, V., Mogessie, B., James, L.C., Schuh, M., A method for the acute and rapid degradation of endogenous proteins. Cell 171 (2017), 1692–1706.e18.
18. Clynes, R., Maizes, J.S., Guinamard, R., Ono, M., Takai, T., Ravetch, J.V., Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189 (1999), 179–185.
19. Coccia, M., Harrison, O.J., Schiering, C., Asquith, M.J., Becher, B., Powrie, F., Maloy, K.J., IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J. Exp. Med. 209 (2012), 1595–1609.
20. Dinarello, C.A., Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27 (2009), 519–550.
21. Fagarasan, S., Evolution, development, mechanism and function of IgA in the gut. Curr. Opin. Immunol. 20 (2008), 170–177.
22. Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.F., Sandborn, W.J., Van Assche, G., Axler, J., Kim, H.J., Danese, S., et al., GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369 (2013), 699–710.
23. Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P.D.R., Wehkamp, J., Feagan, B.G., Yao, M.D., Karczewski, M., et al., Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
24. Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., et al., International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
25. Kaser, A., Zeissig, S., Blumberg, R.S., Inflammatory bowel disease. Annu. Rev. Immunol. 28 (2010), 573–621.
26. Kobayashi, K., Qiao, S.W., Yoshida, M., Baker, K., Lencer, W.I., Blumberg, R.S., An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 137 (2009), 1746–17456.e1.
27. Leiper, K., Martin, K., Ellis, A., Subramanian, S., Watson, A.J., Christmas, S.E., Howarth, D., Campbell, F., Rhodes, J.M., Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60 (2011), 1520–1526.
28. Leppkes, M., Becker, C., Ivanov, I.I., Hirth, S., Wirtz, S., Neufert, C., Pouly, S., Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136 (2009), 257–267.
29. Li, H., Courtois, E.T., Sengupta, D., Tan, Y., Chen, K.H., Goh, J.J.L., Kong, S.L., Chua, C., Hon, L.K., Tan, W.S., et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49 (2017), 708–718.
30. Ligumsky, M., Simon, P.L., Karmeli, F., Rachmilewitz, D., Role of interleukin 1 in inflammatory bowel disease–enhanced production during active disease. Gut 31 (1990), 686–689.
31. Lu, L.L., Chung, A.W., Rosebrock, T.R., Ghebremichael, M., Yu, W.H., Grace, P.S., Schoen, M.K., Tafesse, F., Martin, C., Leung, V., et al. A functional role for antibodies in tuberculosis. Cell 167 (2016), 433–443.e14.
32. Ma, T.K., McAdoo, S.P., Tam, F.W., Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. Nephrol. Dial. Transplant. 32:suppl_1 (2017), i129–i138.
33. Macpherson, A., Khoo, U.Y., Forgacs, I., Philpott-Howard, J., Bjarnason, I., Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38 (1996), 365–375.
34. Marchiando, A.M., Ramanan, D., Ding, Y., Gomez, L.E., Hubbard-Lucey, V.M., Maurer, K., Wang, C., Ziel, J.W., van Rooijen, N., Nuñez, G., et al. A deficiency in the autophagy gene Atg16L1 enhances resistance to enteric bacterial infection. Cell Host Microbe 14 (2013), 216–224.
35. Masuda, A., Yoshida, M., Shiomi, H., Ikezawa, S., Takagawa, T., Tanaka, H., Chinzei, R., Ishida, T., Morita, Y., Kutsumi, H., et al. Fcgamma receptor regulation of Citrobacter rodentium infection. Infect. Immun. 76 (2008), 1728–1737.
36. McGovern, D.P., Kugathasan, S., Cho, J.H., Genetics of inflammatory bowel diseases. Gastroenterology 149 (2015), 1163–1176.e2.
37. Neurath, M.F., Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14 (2014), 329–342.
38. Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008), 34–47.
39. Olsen, J., Gerds, T.A., Seidelin, J.B., Csillag, C., Bjerrum, J.T., Troelsen, J.T., Nielsen, O.H., Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm. Bowel Dis. 15 (2009), 1032–1038.
40. Planell, N., Lozano, J.J., Mora-Buch, R., Masamunt, M.C., Jimeno, M., Ordás, I., Esteller, M., Ricart, E., Piqué, J.M., Panés, J., Salas, A., Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 62 (2013), 967–976.
41. Reinecker, H.C., Steffen, M., Witthoeft, T., Pflueger, I., Schreiber, S., MacDermott, R.P., Raedler, A., Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94 (1993), 174–181.
42. Sandborn, W.J., Gasink, C., Gao, L.L., Blank, M.A., Johanns, J., Guzzo, C., Sands, B.E., Hanauer, S.B., Targan, S., Rutgeerts, P., et al., CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367 (2012), 1519–1528.
43. Schroder, K., Tschopp, J., The inflammasomes. Cell 140 (2010), 821–832.
44. Seo, S.-U., Kamada, N., Muñoz-Planillo, R., Kim, Y.-G., Kim, D., Koizumi, Y., Hasegawa, M., Himpsl, S.D., Browne, H.P., Lawley, T.D., et al. Distinct commensals induce interleukin-1β via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity 42 (2015), 744–755.
45. Shafir, M., Martinelli, G., Bekesi, J.G., Jaramillo, S., Heimann, T., Aufses, A.H. Jr., Immunoglobulins (Ig) in circulating immune complexes (CIC) in cancer and inflammatory bowel disease (IBD). Eur. J. Surg. Oncol. 12 (1986), 351–357.
46. Shaw, M.H., Kamada, N., Kim, Y.G., Núñez, G., Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J. Exp. Med. 209 (2012), 251–258.
47. Smith, K.G., Clatworthy, M.R., FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10 (2010), 328–343.
48. Tamoutounour, S., Henri, S., Lelouard, H., de Bovis, B., de Haar, C., van der Woude, C.J., Woltman, A.M., Reyal, Y., Bonnet, D., Sichien, D., et al. CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. Eur. J. Immunol. 42 (2012), 3150–3166.
49. Thomas, M.G., Bayliss, C., Bond, S., Dowling, F., Galea, J., Jairath, V., Lamb, C., Probert, C., Timperley-Preece, E., Watson, A., et al. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open, 9, 2019, e023765.
50. Uo, M., Hisamatsu, T., Miyoshi, J., Kaito, D., Yoneno, K., Kitazume, M.T., Mori, M., Sugita, A., Koganei, K., Matsuoka, K., et al. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut 62 (2013), 1734–1744.
51. Vanhove, W., Peeters, P.M., Staelens, D., Schraenen, A., Van der Goten, J., Cleynen, I., De Schepper, S., Van Lommel, L., Reynaert, N.L., Schuit, F., et al. Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease. Inflamm. Bowel Dis. 21 (2015), 2673–2682.
52. Weersma, R.K., Crusius, J.B., Roberts, R.L., Koeleman, B.P., Palomino-Morales, R., Wolfkamp, S., Hollis-Moffatt, J.E., Festen, E.A., Meisneris, S., Heijmans, R., et al. Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations. Inflamm. Bowel Dis. 16 (2010), 2080–2089.
53. Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B., Magilavy, D.B., An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363 (2010), 1303–1312.
54. West, N.R., Hegazy, A.N., Owens, B.M.J., Bullers, S.J., Linggi, B., Buonocore, S., Coccia, M., Görtz, D., This, S., Stockenhuber, K., et al., Oxford IBD Cohort Investigators. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23 (2017), 579–589.
55. Willcocks, L.C., Smith, K.G., Clatworthy, M.R., Low-affinity Fcgamma receptors, autoimmunity and infection. Expert Rev. Mol. Med., 11, 2009, e24.
56. Withers, D.R., Hepworth, M.R., Wang, X., Mackley, E.C., Halford, E.E., Dutton, E.E., Marriott, C.L., Brucklacher-Waldert, V., Veldhoen, M., Kelsen, J., et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat. Med. 22 (2016), 319–323.
57. Yang, S.K., Jung, Y., Kim, H., Hong, M., Ye, B.D., Song, K., Association of FCGR2A, JAK2 or HNF4A variants with ulcerative colitis in Koreans. Dig. Liver Dis. 43 (2011), 856–861.
58. Zheng, G.X.Y., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D., McDermott, G.P., Zhu, J., et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun., 8, 2017, 14049.